Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)

INTRODUCTION: Increased dosing of rifampicin and pyrazinamide seems a viable strategy to shorten treatment and prevent relapse of drug-susceptible tuberculosis (TB), but safety and efficacy remains to be confirmed. This clinical trial aims to explore safety and pharmacokinetics-pharmacodynamics of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ekqvist, David, Bornefall, Anna, Augustinsson, Daniel, Sönnerbrandt, Martina, Nordvall, Michaela Jonsson, Fredrikson, Mats, Carlsson, Björn, Sandstedt, Mårten, Simonsson, Ulrika S H, Alffenaar, Jan-Willem C, Paues, Jakob, Niward, Katarina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915351/
https://www.ncbi.nlm.nih.gov/pubmed/35273049
http://dx.doi.org/10.1136/bmjopen-2021-054788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915351/
https://www.ncbi.nlm.nih.gov/pubmed/35273049
http://dx.doi.org/10.1136/bmjopen-2021-054788

Ejemplares similares